In patients who relapse during a treatment-free period after achieving remission on prior 1st/2nd generation TKI, what factors should be taken into consideration when restarting treatment?

I would usually restart therapy in patients who lose MMR after a failed TFR attempt. I would usually use the same TKI they were using before stopping, unless part of the reason for stopping was toxicity, in which case I would consider an alternative TKI that may have a lower probability of having a ...

While an important question to study, we do not yet know if asciminib would yield better outcomes, perhaps focusing on tolerability and/or the ability to successfully attempt a subsequent treatment-free remission, if patients were switched to it after relapsing during a treatment-free remission atte...

Regardless of whether the same or a different TKI is used, most patients who relapse after their original TKI discontinuation rapidly regain major molecular response or deep molecular response upon restarting therapy.

Patient-specific factors such as prior TKI tolerability, comorbidities, patient pre...